오토노믹스 메디컬AMIX 주가

[10-K] 연 실적 — FORM 10-K

Which stocks have an unusual volume on Wednesday?

The trading volume of these stocks is deviating from the norm in today's session.

Why 8x8 Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket

Shares of 8x8 Inc (NASDAQ: EGHT) jumped 13.3% in pre-market trading after reporting better-than-expected Q4 results, with adjusted earnings of 11 cents per share and revenue of $185.25 million. GCL, PETZ, WOK, MEHA, HAO, TDIC, FEED, KELYA, and AMC were among the top gainers, while RUBI, AMIX, IPW, ANVS, and WGRX were among the top losers in pre-market trading.

Let's take a look at the stocks that are in motion in today's session.

Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.

There are notable gap-ups and gap-downs in today's session.

The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.

12 Health Care Stocks Moving In Tuesday's Intraday Session

Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation

Technology unlocks minimally invasive transvascular access to nerve targets and tissues through and beyond the lumen wall Patent strengthens intellectual property foundation for next-generation neuromodulation technologies THE WOODLANDS, TX, May 19, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO)

Autonomix Medical Announces USPTO Issues U.S. Patent Titled Systems, Methods, And Devices For Monitoring And Treatment Of Tissues Within And/Or Through A Lumen Wall

Technology unlocks minimally invasive transvascular access to nerve targets and tissues through and beyond the lumen wallPatent strengthens intellectual property foundation for next-generation neuromodulation

Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation

THE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two abstracts highlighting the Company’s innovative transvascular nerve-targeting platform technology have been accepted for presentation at EuroPCR 2026, the world-leading course in interventional cardiovascular medicine, taking place May 19–22, 2026 in Paris, France. T

[S-8] S-8 — FORM S-8